BioCentury
ARTICLE | Politics, Policy & Law

Buckle-up, turbulence ahead in Washington

What the midterms will mean for biopharma

November 9, 2018 7:53 PM UTC

The midterm elections’ outcome will create deafening political noise about drug prices and great discomfort for pharmaceutical company executives. The effects on the biopharma industry will be tangible, but far more modest than the fiery rhetoric from both sides of Pennsylvania Avenue suggests.

Disdain for drug companies is one of the few areas of agreement between House Democrats and President Donald Trump, but political and parliamentary realities will limit the likelihood the shared anger translates into laws affecting the prices of medicines...